1-3 of 3
Harish Potu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort

Malathi Kandarpa, PhD, Luke F. Peterson, PhD, Harish Potu, PhD, Megha Ramappan, Yihong Liu, Avery Polk, Shaomeng Wang, PhD, Moshe Talpaz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2670.
https://doi.org/10.1182/blood-2019-131949
Published: 2019
Journal Articles

Superior Pre-Clinical Efficacy of Novel Protac Based BET Degrader in a Large Acute Myeloid Leukemia Cohort

Malathi Kandarpa, PhD, Luke F. Peterson, PhD, Harish Potu, PhD, Yihong Liu, Avery Polk, Shaomeng Wang, PhD, Moshe Talpaz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3936.
https://doi.org/10.1182/blood-2019-131759
Published: 2019
Journal Articles

Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies

Luke F. Peterson, Hanshi Sun, Yihong Liu, Harish Potu, Malathi Kandarpa, Monika Ermann, Stephen M. Courtney, Matthew Young, Hollis D. Showalter, Duxin Sun, Andrzej Jakubowiak, Sami N. Malek, Moshe Talpaz, Nicholas J. Donato
Journal: Blood
Blood (2015) 125 (23): 3588–3597.
https://doi.org/10.1182/blood-2014-10-605584
Published: 2015
Includes: Supplemental data